Contrive Datum Insights has published "Computer Aided Diagnostics Cadx Market Size, Share & Industry Analysis, By Type (Mammography, Magnetic Resonance Imaging (MRI), Ultrasound, Tomosynthesis, Computed Tomography (CT)), End use (Hospitals, Clinics, Medical diagnostic centres, Others), Application (Lung Cancer, Liver Cancer, Oncology, Others), Component (Software, Hardware, Services), Deployment mode (On-premise, Cloud-based), and Regional Forecast, 2026-2034". The study sizes the global computer aided diagnostics cadx market at USD 1.08 billion in 2025 and projects growth from USD 1.231 billion in 2026 to USD 3.302 billion by 2034, a compound annual growth rate of 13.13% across the forecast period.
Computer-aided diagnostics software analyzes medical images to flag findings for radiologist review, layered on modalities such as mammography, CT, MRI and ultrasound. Buyers are hospitals, standalone imaging and diagnostic centres, and specialty clinics that need faster, more consistent reads across high imaging volumes. The category spans on-premise workstation software and cloud-hosted algorithms, sold as licensed modules or subscription services alongside the imaging equipment itself.
Expanding regulatory clearances for AI-based reading algorithms
Expanding regulatory clearances for AI-based reading algorithms is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 13.13% a year, the type lines exposed to it move fastest: Tomosynthesis compounds at 18.2%, taking its share of revenue from 7.96% to 11.99% and its value from USD 0.086 billion to USD 0.396 billion.
A more favourable outcome is possible. If regulatory clearances extend to additional indications faster than the base case assumes, and public screening-program budgets grow without interruption through the forecast period, 2034 revenue reaches USD 3.698 billion instead of the USD 3.302 billion the base case carries.
On the downside, reimbursement policy for AI-assisted reads lags clearance activity, and hospital IT budget cycles delay integration projects beyond the base case timeline, which would hold 2034 revenue to USD 2.906 billion. Mammography, which carries 34.07% of 2025 revenue, already grows at only 10.71% against the market's 13.13%, so the largest part of the base is also its slowest.
Mammography Scale Against Tomosynthesis Momentum
The type axis, not the regional one, is what divides the field. Mammography is the volume position, 34.07% of 2025 revenue at USD 0.368 billion, holding 28.01% through 2034, and it is defended by scale. Tomosynthesis is the growth position at 18.2%, and it is open. Strength in one does not carry into the other.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| End use | Hospitals | 51.94% · USD 0.561 billion | Medical diagnostic centres 15.53% |
| Application | Lung Cancer | 37.96% · USD 0.41 billion | — |
| Component | Software | 55% · USD 0.594 billion | — |
| Deployment mode | On-premise | 63.98% · USD 0.691 billion | Cloud-based 18.43% |
- Based on regional analysis, North America led the global computer aided diagnostics cadx market in 2025 with 42.04% of global revenue at USD 0.454 billion, reaching USD 1.255 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 23.98% in 2025 to 30.01% in 2034, with revenue growing from USD 0.259 billion to USD 0.991 billion.
- Middle East and Africa remains the smallest region throughout, at 2.96% of 2025 revenue and 3% by 2034.
- Mammography was the leading type line in 2025, taking 34.07% of revenue at USD 0.368 billion.
- No type line grows faster than Tomosynthesis, at a projected 18.2%.
- The United States is the largest single country market at USD 0.372 billion in 2025, 34.44% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by type, and by end use, application, component and deployment mode. The headline total carries bear, base and bull cases at USD 2.906 billion and USD 3.698 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.